Blueprint Genetics OY, Keilaranta, Espoo, Finland.
Blueprint Genetics Inc, Seattle, WA, USA.
Transl Vis Sci Technol. 2022 Jan 3;11(1):6. doi: 10.1167/tvst.11.1.6.
Comprehensive genetic testing for inherited retinal dystrophy (IRD) is challenged by difficult-to-sequence genomic regions, which are often mutational hotspots, such as RPGR ORF15. The purpose of this study was to evaluate the diagnostic contribution of RPGR variants in an unselected IRD patient cohort referred for testing in a clinical diagnostic laboratory.
A total of 5201 consecutive patients were analyzed with a clinically validated next-generation sequencing (NGS)-based assay, including the difficult-to-sequence RPGR ORF15 region. Copy number variant (CNV) detection from NGS data was included. Variant interpretation was performed per the American College of Medical Genetics and Genomics guidelines.
A confirmed molecular diagnosis in RPGR was found in 4.5% of patients, 24.0% of whom were females. Variants in ORF15 accounted for 74% of the diagnoses; 29% of the diagnostic variants were in the most difficult-to-sequence central region of ORF15 (c.2470-3230). Truncating variants made up the majority (91%) of the diagnostic variants. CNVs explained 2% of the diagnostic cases, of which 80% were one- or two-exon deletions outside of ORF15.
Our findings indicate that high-throughput, clinically validated NGS-based testing covering the difficult-to-sequence region of ORF15, in combination with high-resolution CNV detection, can help to maximize the diagnostic yield for patients with IRD.
These results demonstrate an accurate and scalable method for the detection of RPGR-related variants, including the difficult-to-sequence ORF15 hotspot, which is relevant given current and emerging therapeutic opportunities.
遗传性视网膜营养不良(IRD)的综合基因检测受到难以测序的基因组区域的挑战,这些区域通常是突变热点,如 RPGR ORF15。本研究旨在评估 RPGR 变体在一个未经选择的 IRD 患者队列中的诊断贡献,这些患者在临床诊断实验室中进行了检测。
对 5201 例连续患者进行了一项临床验证的下一代测序(NGS)检测,包括难以测序的 RPGR ORF15 区域。从 NGS 数据中检测拷贝数变异(CNV)。根据美国医学遗传学与基因组学学院的指南进行变体解释。
在 4.5%的患者中发现了 RPGR 的明确分子诊断,其中 24.0%为女性。ORF15 中的变体占诊断的 74%;诊断变体的 29%位于 ORF15 最难以测序的中央区域(c.2470-3230)。截断变体构成了大多数(91%)的诊断变体。CNVs 解释了 2%的诊断病例,其中 80%是 ORF15 之外的一个或两个外显子缺失。
我们的研究结果表明,高通量、临床验证的基于 NGS 的检测方法可覆盖 ORF15 中难以测序的区域,并结合高分辨率的 CNV 检测,可帮助最大限度地提高 IRD 患者的诊断率。
医学博士,临床分子遗传学专家